Richard L Miller

Summary

Country: USA

Publications

  1. ncbi request reprint Synthesis and structure-activity-relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production
    John F Gerster
    3M Pharmaceuticals, 3M Center, Building 270 4S 02, St Paul, Minnesota 55144 1000, USA
    J Med Chem 48:3481-91. 2005
  2. ncbi request reprint Resiquimod and other immune response modifiers as vaccine adjuvants
    Mark A Tomai
    3M Drug Delivery Systems, 3M Center, 275 3E 10 St Paul, MN 55144, USA
    Expert Rev Vaccines 6:835-47. 2007
  3. ncbi request reprint The antiviral activity of Toll-like receptor 7 and 7/8 agonists
    Richard L Miller
    Drug News Perspect 21:69-87. 2008
  4. ncbi request reprint Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents
    Yonghong Shi
    Division of Molecular and Cellular Biology, Research Institute, Sunnybrook Health Sciences Center, 2075 Bayview Avenue, Toronto, Ontario, Canada
    Cancer Res 67:1823-31. 2007
  5. ncbi request reprint Apoptotic responses in squamous carcinoma and epithelial cells to small-molecule toll-like receptor agonists evaluated with automated cytometry
    Jon R Inglefield
    Department of Pharmacology, 3M Inc, Pharmaceuticals Division, St Paul, Minnesota 55144 1000, USA
    J Biomol Screen 11:575-85. 2006
  6. ncbi request reprint Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity
    Jelena Tomic
    Division of Molecular and Cellular Biology, Research Institute, Sunnybrook and Women s College Health Sciences Center, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada
    J Immunol 176:3830-9. 2006
  7. ncbi request reprint Topical imiquimod treatment prevents UV-light induced loss of contact hypersensitivity and immune tolerance
    Thomas H Thatcher
    Division of Pulmonary and Critical Care Medicine, University of Rochester School of Medicine, Rochester, New York, USA
    J Invest Dermatol 126:821-31. 2006
  8. ncbi request reprint Human TLR-7-, -8-, and -9-mediated induction of IFN-alpha/beta and -lambda Is IRAK-4 dependent and redundant for protective immunity to viruses
    Kun Yang
    Laboratory of Human Genetics of Infectious Diseases, University of Paris René Descartes INSERM U550, Necker Medical School, 75015 Paris, France
    Immunity 23:465-78. 2005
  9. ncbi request reprint Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod
    David E Spaner
    Division of Molecular and Cellular Biology, Research Institute, Sunnybrook and Women s College Health Sciences Center, Toronto, Canada
    Leuk Lymphoma 46:935-9. 2005
  10. ncbi request reprint Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod
    Sheila J Gibson
    Department of Pharmacology, 3M Pharmaceuticals, 3M Center, 270 2S 06, St Paul, MN 55144 1000, USA
    Cell Immunol 218:74-86. 2002

Collaborators

  • D E Spaner
  • Patricia Fitzgerald-Bocarsly
  • Mark A Tomai
  • Yonghong Shi
  • Sheila J Gibson
  • Dionne White
  • Liwei He
  • Jon R Inglefield
  • Jelena Tomic
  • Thomas H Thatcher
  • John F Gerster
  • Kun Yang
  • John P Vasilakos
  • Kenneth E Lipson
  • William C Kieper
  • Isidro E Zarraga
  • Jenny Mena
  • Irina Luzina
  • Anthony A Gaspari
  • Caitlin Hammond
  • Rita Fishelevich
  • Hervé Lebrec
  • Christopher J Larson
  • Michel Lupu
  • Sami Al-Hajjar
  • Armanda Casrouge
  • Franck J Barrat
  • Linda M Imbertson
  • Yvon Bastard
  • Laszlo Marodi
  • Frederic Geissmann
  • Jean Denis Andre
  • Sharon E Pecore
  • Pierre Lebon
  • Nickolas Nikolaides
  • Tammy L Wagner
  • Folakemi Y Oneyemi
  • David Speert
  • Chaim Roifman
  • Joel R Jacobson
  • Donald Davidson
  • Woubalem Birmachu
  • Xiaoxia Li
  • Sabine Plancoulaine
  • Peter V Maye
  • Horst von Bernuth
  • Daniel Lagain
  • Ben Zion Garty
  • Gwen J Parkhurst
  • Cheng Lung Ku
  • Anne Puel
  • Tracy L Testerman
  • Roy T Knafla
  • Shenying Zhang
  • Brigitte Senechal
  • Natalie J Thompson
  • Helen Chapel
  • Michael J Reiter
  • Shannon N Bomersine
  • Lisa S Scribner
  • Jean Laurent Casanova
  • Kyle J Lindstrom
  • Abdulaziz Al-Ghonaium
  • Celine Eidenschenk
  • Capucine Picard
  • Shiela J Gibson
  • Robert L Coffman
  • Emmanuelle Jouanguy
  • Carlos Rodriguez-Gallego
  • Adrian Ozinsky
  • Charles E Weeks
  • JoAnn L Oesterich
  • Keith B Gorden
  • Tony R Riter
  • Lisa M Rogers
  • Ross M Kedl
  • Scott W McKane
  • Jana M Lindh
  • Ashley E Fuller
  • Randy J Noelle
  • Raymond M Gleason
  • Xiaohong Qiu

Detail Information

Publications10

  1. ncbi request reprint Synthesis and structure-activity-relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production
    John F Gerster
    3M Pharmaceuticals, 3M Center, Building 270 4S 02, St Paul, Minnesota 55144 1000, USA
    J Med Chem 48:3481-91. 2005
    ....
  2. ncbi request reprint Resiquimod and other immune response modifiers as vaccine adjuvants
    Mark A Tomai
    3M Drug Delivery Systems, 3M Center, 275 3E 10 St Paul, MN 55144, USA
    Expert Rev Vaccines 6:835-47. 2007
    ..For injection, resiquimod or a similar compound may need to be formulated to allow for local immune activation without induction of systemic cytokines...
  3. ncbi request reprint The antiviral activity of Toll-like receptor 7 and 7/8 agonists
    Richard L Miller
    Drug News Perspect 21:69-87. 2008
    ..This review focuses on the mechanism of action and antiviral usage reported for the TLR7 agonist imiquimod, the TLR7/8 agonist resiquimod and related imidazoquinoline analogues...
  4. ncbi request reprint Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents
    Yonghong Shi
    Division of Molecular and Cellular Biology, Research Institute, Sunnybrook Health Sciences Center, 2075 Bayview Avenue, Toronto, Ontario, Canada
    Cancer Res 67:1823-31. 2007
    ..This property of the TLR7-tolerized state may potentially be exploited in the treatment of B cell cancers...
  5. ncbi request reprint Apoptotic responses in squamous carcinoma and epithelial cells to small-molecule toll-like receptor agonists evaluated with automated cytometry
    Jon R Inglefield
    Department of Pharmacology, 3M Inc, Pharmaceuticals Division, St Paul, Minnesota 55144 1000, USA
    J Biomol Screen 11:575-85. 2006
    ..This TUNEL analysis allows the quantitative comparison of compounds' apoptotic activity toward adherent malignant and normal cells and may be useful for hit characterization after a screen...
  6. ncbi request reprint Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity
    Jelena Tomic
    Division of Molecular and Cellular Biology, Research Institute, Sunnybrook and Women s College Health Sciences Center, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada
    J Immunol 176:3830-9. 2006
    ..These findings suggest that TLR-7 "licenses" human B cells to respond to cytokines of the adaptive immune system (such as IL-2) and provide a strategy to increase the immunogenicity of lymphoma cells for therapeutic purposes...
  7. ncbi request reprint Topical imiquimod treatment prevents UV-light induced loss of contact hypersensitivity and immune tolerance
    Thomas H Thatcher
    Division of Pulmonary and Critical Care Medicine, University of Rochester School of Medicine, Rochester, New York, USA
    J Invest Dermatol 126:821-31. 2006
    ....
  8. ncbi request reprint Human TLR-7-, -8-, and -9-mediated induction of IFN-alpha/beta and -lambda Is IRAK-4 dependent and redundant for protective immunity to viruses
    Kun Yang
    Laboratory of Human Genetics of Infectious Diseases, University of Paris René Descartes INSERM U550, Necker Medical School, 75015 Paris, France
    Immunity 23:465-78. 2005
    ..The TLR-7-, TLR-8-, and TLR-9-dependent induction of IFN-alpha/beta and -lambda is strictly IRAK-4 dependent and paradoxically redundant for protective immunity to most viruses in humans...
  9. ncbi request reprint Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod
    David E Spaner
    Division of Molecular and Cellular Biology, Research Institute, Sunnybrook and Women s College Health Sciences Center, Toronto, Canada
    Leuk Lymphoma 46:935-9. 2005
    ..These observations extend the therapeutic spectrum of imiquimod to cutaneous B-cell lymphomas and suggest the use of TLR-7/8 agonists in CLL immunotherapy...
  10. ncbi request reprint Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod
    Sheila J Gibson
    Department of Pharmacology, 3M Pharmaceuticals, 3M Center, 270 2S 06, St Paul, MN 55144 1000, USA
    Cell Immunol 218:74-86. 2002
    ..These results demonstrate that imidazoquinoline molecules directly induce pDC maturation as determined by cytokine induction, CCR7 and co-stimulatory marker expression and prolonging viability...